BioSpace News Archive

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 9,100 shares of the Company’s common stock at an exercise price per share of $27.80, which was the closing price on October 24, 2022, and restricted stock units to acquire a total of 4,550 shares of the Company’s common stock.

Juno Diagnostics™ (JunoDx™), a company focused on bringing vital health information to patients by improving access, affordability, and transparency, today announced participation in the Credit Suisse 31st Annual Healthcare Conference, being held on November 7-10, 2022, in Rancho Palos Verdes, CA.

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that members of its management team are scheduled to participate in Credit Suisse’s 31st Annual Healthcare Conference on Tuesday, November 8, 2022.

Masimo (NASDAQ: MASI) will release third quarter 2022 financial results for the period ended October 1, 2022, after the market closes on Tuesday, November 8, 2022.

Varex Imaging Corporation (Nasdaq: VREX) today announced that it will report unaudited financial results for the fourth quarter and full fiscal year 2022 following the close of regular trading on Tuesday, November 15, 2022.

Senseonics Holdings, Inc. announced that it plans to release its third quarter 2022 financial results after market close on Tuesday, November 8, 2022.

The global artificial intelligence in cancer diagnostics market size was estimated at USD 367.71 million in 2021 and it is expected to surpass around USD 5.3 billion by 2030, poised to grow at a CAGR of 34.51% from 2022 to 2030.

According to Latest Report Study, the global DNA synthesis market was surpassed at USD 260.7 million in 2021 and is expected to hit around USD 513.80 million by 2030, growing at a CAGR of 7.83% from 2022 to 2030.

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) today announced that the Company expects to report financial and business results for the third quarter of 2022 after the market closes on Tuesday, November 8, 2022.

STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2023 second quarter financial results at 10:00 a.m. ET on November 10, 2022.